| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.26 M USD | -8.69 M USD | -84.53 M USD | -76.47 M USD | -23.12 M USD | -4.98 M USD |
| Depreciation & Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — |
| Capital Expenditures | — | — | — | — | — | — |
| Cash Flow from Investing | — | — | — | — | — | — |
| Cash Flow from Financing | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -32.83 M USD | -117.03 M USD | -82.44 M USD | -80.23 M USD | -52.41 M USD | -5.38 M USD |
Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders. Its primary product candidate, simufilam, is an investigational oral small molecule drug currently advancing in preclinical studies for tuberous sclerosis complex (TSC)-related epilepsy, where it has shown reductions in seizure activity in mouse models. The company previously explored simufilam and the diagnostic SavaDx for Alzheimer's disease but discontinued that program following Phase 3 trial results. Cassava Sciences Inc. conducts research emphasizing unmet needs in neurodegenerative and neurological conditions, supported by a team of experienced professionals in neuroscience, clinical development, and regulatory affairs. Headquartered in Austin, Texas since its name change in 2019, and founded in 1998, the company maintains a streamlined operation dedicated to advancing its pipeline through proof-of-concept studies and strategic hires in epilepsy therapeutics.